Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias

Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------

Interim Data from a Phase 2 Clinicial Trial in B-Precursor Acute
Lymphoblastic Leukemia Show
that Blinatumomab Is Able to Eliminate Minimal Residual Disease

Bethesda, MD, December 8, 2008 -- Micromet, Inc. (Nasdaq: MITI), a
biopharmaceutical company developing novel, proprietary antibodies
for the treatment of cancer, inflammation and autoimmune diseases,
yesterday presented first interim data from a phase 2 clinical trial
of BiTE® antibody blinatumomab (MT103/MEDI-538) in patients with
acute lymphoblastic leukemia (ALL). Blinatumomab is a novel
therapeutic antibody that activates a patient's T cells to seek out
and destroy cancer cells. The presentation took place at the 50th
annual meeting of the American Society of Hematology, held December 6
to 9 in San Francisco, CA.

The patients in this phase 2 clinical trial are in complete
hematological remission following intense chemotherapy regimens, but
retain ALL cancer cells in their bone marrow - so called minimal
residual disease (MRD). Various reports have confirmed that ALL
patients with MRD following chemotherapy have a significantly worse
prognosis than patients without MRD. Interim results for the ongoing
phase 2 clinical trial of blinatumomab for ALL find the BiTE antibody
was able to eliminate MRD. Six patients have been enrolled so far in
the trial. Four patients have concluded at least two cycles of
therapy with blinatumomab. Three out of these four patients turned
MRD-negative after the first treatment cycle. One patient achieved
stable disease after the first treatment cycle and does not show
signs of hematological relapse to date. Except for one patient with a
port infection, no severe toxicities were recorded so far.

"Today patients with MRD-positive ALL after first line therapy have
very few options for treatment, and a very high likelihood of
relapse," commented Professor D. Hoelzer, chairman of the German
Multicenter Study Group for Adult Acute Lymphoblastic Leukemia
(GMALL). "The ability to convert a patient's MRD status from
positive to negative could lead to better clinical outcomes. These
data suggest that blinatumomab may hold the potential to be an
effective consolidation therapy after prior incomplete response to
chemotherapy or even targeted therapy."

(more)

"The level of response to blinatumomab in ALL patients observed in
this trial combined with the unmet need for new therapies to treat
this patient population may open the path towards an accelerated
development in this indication," commented Micromet Senior Vice
President and Chief Medical Officer Carsten Reinhardt, M.D.

Micromet will hold a webcast and conference call on Monday, December
8 at 2:00 pm EST to discuss this study and other blinatumomab data
presented at the conference. To access the webcast and view the
powerpoint presentation, please log on
to: http://webcasts.micromet-inc.com. To participate in the
conference call, dial 866-700-7441 (U.S.) or 617-213-8839
(international), passcode: 39298646.

About BiTE Antibodies

BiTE® antibodies are designed to direct the body's cytotoxic, or
cell- destroying, T cells against tumor cells, and represent a new
therapeutic approach to cancer therapy. Typically antibodies cannot
engage T cells because T cells lack the appropriate receptors for
binding antibodies. Previous attempts have shown the potential of T
cells to treat cancer, but the therapeutic approaches tested to date
have been hampered by cancer cells' ability to escape recognition by
T cells. The use of BiTE antibodies that are specifically designed to
engage T cells for attacking cancer cells may provide a more
effective anti-tumor approach than conventional monoclonal
antibodies.

About Micromet, Inc.

Micromet, Inc. (www.micromet-inc.com) is a biopharmaceutical company
with offices in Bethesda, Maryland and Munich, Germany. The Company
is developing novel, proprietary antibodies for the treatment of
cancer, inflammation and autoimmune diseases. The Company uses its
proprietary BiTE® antibody platform to create a new class of
antibodies that specifically activate T cells from the patient's own
immune system to eliminate cancer cells or other disease-related
cells. Four of the Company's antibodies are currently in clinical
trials, with the remainder of its product pipeline in preclinical
development. The Company's lead program is a BiTE antibody known as
blinatumomab, or MT103. It is in a phase 2 clinical trial for the
treatment of patients with acute lymphoblastic leukemia and a phase 1
clinical trial for the treatment of patients with non-Hodgkin's
lymphoma. Micromet is developing blinatumomab in collaboration with
MedImmune, a subsidiary of AstraZeneca plc. Micromet's second BiTE
antibody in clinical development is MT110, which targets the
epithelial cell

(more)

adhesion molecule (EpCAM). The Company owns all rights to MT 110,
which is currently in a phase 1 clinical trial for the treatment of
patients with solid tumors. The Company's third clinical stage
antibody is adecatumumab, also known as MT201, a conventional human
monoclonal antibody that targets EpCAM-expressing solid tumors.
Micromet is developing adecatumumab in collaboration with Merck
Serono in a phase 1b clinical trial evaluating adecatumumab in
combination with docetaxel for the treatment of patients with
metastatic breast cancer. Micromet has licensed a fourth clinical
stage antibody, MT293, to TRACON Pharmaceuticals, Inc. MT293 is being
developed in a phase 1 clinical trial for the treatment of patients
with cancer. The Company's preclinical programs include MT203, which
is being developed in collaboration with Nycomed. MT203 is a
traditional human antibody neutralizing the activity of
granulocyte/macrophage colony stimulating factor (GM-CSF), which has
potential applications in the treatment of inflammatory and
autoimmune diseases, such as rheumatoid arthritis, psoriasis, or
multiple sclerosis. Additional BiTE antibodies, targeting CEA, CD33,
Her2, EGFR and MCSP, respectively, are in different stages of
preclinical development.

Forward-Looking Statements

This release contains certain forward-looking statements that involve
risks and uncertainties that could cause actual results to be
materially different from historical results or from any future
results expressed or implied by such forward-looking statements.
These forward-looking statements include statements regarding the
efficacy and intended utilization of our product candidates and the
development of our BiTE antibody technology. You are urged to
consider statements that include the words "may," "potential," or the
negative of those words or other similar words to be uncertain and
forward-looking. Factors that may cause actual results to differ
materially from any future results expressed or implied by any
forward-looking statements include the risk that product candidates
that appeared promising in early research, preclinical studies or
clinical trials do not demonstrate safety and/or efficacy in
subsequent clinical trials, the risk that encouraging results from
early research, preclinical studies or clinical trials may not be
confirmed upon further analysis of the detailed results of such
research, preclinical study or clinical trial, and the risk that
additional information relating to the safety, efficacy or
tolerability of our product candidates may be discovered upon further
analysis of preclinical or clinical trial data. These factors and
others are more fully discussed in Micromet's Quarterly Report on
Form 10-Q for the fiscal quarter ended September 30, 2008, filed with
the SEC on November 6, 2008, as well as other filings by the company
with the SEC.

(more)

Any forward-looking statements are made pursuant to Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, and, as such, speak only
as of the date made. Micromet, Inc. undertakes no obligation to
publicly update any forward-looking statements, whether as a result
of new information, future events or otherwise.

# # #

Contact Information

US Media: European Media:
Andrea tenBroek/Chris Stamm Ludger Wess
(781)-684-0770 +49 (40) 8816 5964
micromet@schwartz-pr.com ludger@akampion.com

US Investors: European Investors:
Susan Noonan Ines-Regina Buth
(212) 966-3650 +49 (30) 2363 2768
susan@sanoonan.com ines@akampion.com

--- End of Message ---

Micromet Inc.
6707 Democracy Boulevard, Suite 505 Bethesda USA

WKN:
A0JMQD; ISIN: US59509C1053;
Listed: Xetra Stars in Frankfurter Wertpapierbörse;
Copyright © Hugin AS 2008. All rights reserved.